NASDAQ:SGYP - Synergy Pharmaceuticals Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$1.63 -0.05 (-2.98 %)
(As of 05/27/2018 03:47 AM ET)
Previous Close$1.63
Today's Range$1.61 - $1.69
52-Week Range$1.42 - $4.84
Volume1.83 million shs
Average Volume3.60 million shs
Market Capitalization$414.52 million
P/E Ratio-1.60
Dividend YieldN/A
Beta1.22

About Synergy Pharmaceuticals (NASDAQ:SGYP)

Synergy Pharmaceuticals logoSynergy Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies to treat gastrointestinal diseases and disorders. Its lead product is plecanatide, a novel uroguanylin based gastrointestinal platform that is traded under the TRULANCE name for the treatment of chronic idiopathic constipation and irritable bowel syndrome. The company also develops dolcanatide to treat mild-to-moderate ulcerative colitis. It has a licensing agreement with Cipher Pharmaceuticals Inc. to develop, market, distribute, and sell TRULANCE in Canada. Synergy Pharmaceuticals Inc. is headquartered in New York, New York.

Receive SGYP News and Ratings via Email

Sign-up to receive the latest news and ratings for SGYP and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
SymbolNASDAQ:SGYP
CUSIP87163930
Phone212-297-0020

Debt

Debt-to-Equity Ratio-3.01
Current Ratio3.09
Quick Ratio2.71

Price-To-Earnings

Trailing P/E Ratio-1.60
Forward P/E Ratio-2.76
P/E GrowthN/A

Sales & Book Value

Annual Sales$16.82 million
Price / Sales23.91
Cash FlowN/A
Price / CashN/A
Book Value($0.16) per share
Price / Book-10.19

Profitability

EPS (Most Recent Fiscal Year)($1.02)
Net Income$-224,330,000.00
Net Margins-773.82%
Return on Equity-652.66%
Return on Assets-145.45%

Miscellaneous

Employees313
Outstanding Shares246,740,000

Synergy Pharmaceuticals (NASDAQ:SGYP) Frequently Asked Questions

What is Synergy Pharmaceuticals' stock symbol?

Synergy Pharmaceuticals trades on the NASDAQ under the ticker symbol "SGYP."

How were Synergy Pharmaceuticals' earnings last quarter?

Synergy Pharmaceuticals Inc (NASDAQ:SGYP) posted its quarterly earnings data on Thursday, May, 10th. The biopharmaceutical company reported ($0.15) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.16) by $0.01. The biopharmaceutical company earned $8.59 million during the quarter, compared to analyst estimates of $11.18 million. Synergy Pharmaceuticals had a negative return on equity of 652.66% and a negative net margin of 773.82%. The company's revenue for the quarter was up 776.5% on a year-over-year basis. During the same period last year, the company earned ($0.30) EPS. View Synergy Pharmaceuticals' Earnings History.

What price target have analysts set for SGYP?

8 brokerages have issued 1-year target prices for Synergy Pharmaceuticals' stock. Their forecasts range from $2.50 to $15.00. On average, they expect Synergy Pharmaceuticals' share price to reach $8.8125 in the next year. View Analyst Ratings for Synergy Pharmaceuticals.

What are Wall Street analysts saying about Synergy Pharmaceuticals stock?

Here are some recent quotes from research analysts about Synergy Pharmaceuticals stock:
  • 1. According to Zacks Investment Research, "Synergy Pharmaceuticals, Inc. is a biopharmaceutical company focused primarily on the development of drugs to treat gastrointestinal disorders and diseases. Its lead drug candidate plecanatide is a guanylyl cyclase C receptor agonist, to treat GI disorders, primarily chronic constipation and constipation-predominant- irritable bowel syndrome. It is also engaged in developing receptor agonist for the treatment of gastrointestinal inflammatory diseases, such as ulcerative colitis. Synergy Pharmaceuticals, Inc. is headquartered in New York, New York. " (5/9/2018)
  • 2. Cantor Fitzgerald analysts commented, "As we predicted in a report published last week, SGYP disclosed that the cash balance at the end of January exceeded the $128 million level required to access $100 million from the CRG Term Loan Agreement." (2/1/2018)

Are investors shorting Synergy Pharmaceuticals?

Synergy Pharmaceuticals saw a increase in short interest during the month of May. As of May 15th, there was short interest totalling 62,620,901 shares, an increase of 0.3% from the April 30th total of 62,433,759 shares. Based on an average trading volume of 4,543,178 shares, the days-to-cover ratio is presently 13.8 days. Currently, 25.4% of the company's shares are short sold.

Who are some of Synergy Pharmaceuticals' key competitors?

Who are Synergy Pharmaceuticals' key executives?

Synergy Pharmaceuticals' management team includes the folowing people:
  • Dr. Gary S. Jacob, Exec. Chairman (Age 71)
  • Mr. Troy Hamilton Pharm.D., CEO & Director (Age 46)
  • Dr. Kunwar Shailubhai, Chief Scientific Officer and Exec. VP (Age 60)
  • Dr. Patrick H. Griffin M.D., FACP, Exec. VP & Chief Medical Officer (Age 63)
  • Mr. Gary G. Gemignani, Exec. VP & CFO (Age 53)

Has Synergy Pharmaceuticals been receiving favorable news coverage?

Media stories about SGYP stock have trended somewhat positive this week, according to Accern Sentiment. Accern rates the sentiment of news coverage by monitoring more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Synergy Pharmaceuticals earned a media sentiment score of 0.13 on Accern's scale. They also gave media coverage about the biopharmaceutical company an impact score of 46.77 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock's share price in the near term.

Who are Synergy Pharmaceuticals' major shareholders?

Synergy Pharmaceuticals' stock is owned by a variety of of retail and institutional investors. Top institutional investors include BlackRock Inc. (8.62%), Hikari Power Ltd (0.81%), JPMorgan Chase & Co. (0.74%), CVI Holdings LLC (0.72%), Schwab Charles Investment Management Inc. (0.50%) and UBS Group AG (0.47%). Company insiders that own Synergy Pharmaceuticals stock include Gary S Jacob, John P Brancaccio and Paulson & Co Inc. View Institutional Ownership Trends for Synergy Pharmaceuticals.

Which major investors are selling Synergy Pharmaceuticals stock?

SGYP stock was sold by a variety of institutional investors in the last quarter, including UBS Group AG, JPMorgan Chase & Co., BlackRock Inc., Granite Investment Partners LLC and Clear Harbor Asset Management LLC. View Insider Buying and Selling for Synergy Pharmaceuticals.

Which major investors are buying Synergy Pharmaceuticals stock?

SGYP stock was purchased by a variety of institutional investors in the last quarter, including CVI Holdings LLC, Millennium Management LLC, OMERS ADMINISTRATION Corp, Schwab Charles Investment Management Inc., Mackay Shields LLC, Hikari Power Ltd and MetLife Investment Advisors LLC. Company insiders that have bought Synergy Pharmaceuticals stock in the last two years include Gary S Jacob and John P Brancaccio. View Insider Buying and Selling for Synergy Pharmaceuticals.

How do I buy shares of Synergy Pharmaceuticals?

Shares of SGYP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Synergy Pharmaceuticals' stock price today?

One share of SGYP stock can currently be purchased for approximately $1.63.

How big of a company is Synergy Pharmaceuticals?

Synergy Pharmaceuticals has a market capitalization of $414.52 million and generates $16.82 million in revenue each year. The biopharmaceutical company earns $-224,330,000.00 in net income (profit) each year or ($1.02) on an earnings per share basis. Synergy Pharmaceuticals employs 313 workers across the globe.

How can I contact Synergy Pharmaceuticals?

Synergy Pharmaceuticals' mailing address is 420 LEXINGTON AVENUE SUITE 2012, NEW YORK NY, 10170. The biopharmaceutical company can be reached via phone at 212-297-0020 or via email at [email protected]


MarketBeat Community Rating for Synergy Pharmaceuticals (SGYP)

Community Ranking:  3.5 out of 5 (star star star half star)
Outperform Votes:  539 (Vote Outperform)
Underperform Votes:  228 (Vote Underperform)
Total Votes:  767
MarketBeat's community ratings are surveys of what our community members think about Synergy Pharmaceuticals and other stocks. Vote "Outperform" if you believe SGYP will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SGYP will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Synergy Pharmaceuticals (NASDAQ:SGYP) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
8 Wall Street analysts have issued ratings and price targets for Synergy Pharmaceuticals in the last 12 months. Their average twelve-month price target is $8.8125, suggesting that the stock has a possible upside of 440.64%. The high price target for SGYP is $15.00 and the low price target for SGYP is $2.50. There are currently 3 hold ratings and 5 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.632.632.672.80
Ratings Breakdown: 0 Sell Rating(s)
3 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
3 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
3 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
0 Hold Rating(s)
9 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $8.8125$8.8125$8.9444$8.40
Price Target Upside: 440.64% upside361.39% upside325.93% upside341.18% upside

Synergy Pharmaceuticals (NASDAQ:SGYP) Consensus Price Target History

Price Target History for Synergy Pharmaceuticals (NASDAQ:SGYP)

Synergy Pharmaceuticals (NASDAQ:SGYP) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/14/2018BTIG ResearchSet Price TargetBuy$7.00LowView Rating Details
5/13/2018HC WainwrightSet Price TargetBuy$7.00LowView Rating Details
5/13/2018OppenheimerReiterated RatingHoldLowView Rating Details
2/1/2018Cantor FitzgeraldReiterated RatingBuyHighView Rating Details
1/5/2018CIBCReiterated RatingOutperform ➝ Market PerformHighView Rating Details
1/5/2018CitigroupDowngradeMarket PerformHighView Rating Details
11/12/2017Canaccord GenuitySet Price TargetBuy$13.00N/AView Rating Details
8/10/2017Rodman & RenshawLower Price TargetBuy ➝ Buy$18.00 ➝ $15.00HighView Rating Details
3/2/2017GuggenheimReiterated RatingOutperform$10.00N/AView Rating Details
12/15/2016Roth CapitalReiterated RatingBuy$6.50N/AView Rating Details
(Data available from 5/27/2016 forward)

Earnings

Synergy Pharmaceuticals (NASDAQ:SGYP) Earnings History and Estimates Chart

Earnings by Quarter for Synergy Pharmaceuticals (NASDAQ:SGYP)

Synergy Pharmaceuticals (NASDAQ:SGYP) Earnings Estimates

2018 EPS Consensus Estimate: ($0.57)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20181($0.15)($0.15)($0.15)
Q2 20181($0.15)($0.15)($0.15)
Q3 20181($0.14)($0.14)($0.14)
Q4 20181($0.13)($0.13)($0.13)

Synergy Pharmaceuticals (NASDAQ SGYP) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/10/2018Q1 2018($0.16)($0.15)$11.18 million$8.59 millionViewN/AView Earnings Details
3/1/2018Q4 2017($0.19)($0.16)$7.12 million$9.40 millionViewListenView Earnings Details
11/9/2017Q3 2017($0.28)($0.22)$4.53 million$5.01 millionViewN/AView Earnings Details
8/9/2017Q2 2017($0.25)($0.33)$1.98 million$2.31 millionViewN/AView Earnings Details
5/10/2017Q1 2017($0.2260)($0.30)$0.10 million$0.10 millionViewN/AView Earnings Details
3/1/2017Q4 2016($0.20)($0.31)ViewN/AView Earnings Details
11/9/2016Q3 2016($0.22)($0.22)ViewN/AView Earnings Details
8/8/2016Q216($0.20)($0.23)ViewN/AView Earnings Details
5/10/2016Q1($0.23)($0.51)ViewN/AView Earnings Details
2/25/2016Q4 2015($0.25)($0.27)ViewN/AView Earnings Details
11/9/2015Q315($0.28)($0.23)ViewN/AView Earnings Details
8/10/2015Q215($0.28)($0.34)$102.00 millionViewN/AView Earnings Details
5/11/2015Q115($0.33)($0.28)ViewN/AView Earnings Details
3/16/2015($0.28)($0.32)ViewN/AView Earnings Details
11/10/2014($0.28)($0.24)ViewN/AView Earnings Details
8/11/2014($0.23)($0.28)ViewN/AView Earnings Details
5/13/2014Q114($0.23)($0.18)ViewN/AView Earnings Details
3/17/2014Q4 13($0.20)($0.22)ViewN/AView Earnings Details
11/12/2013Q3($0.17)($0.15)ViewN/AView Earnings Details
8/9/2013Q2 2013($0.23)($0.13)ViewN/AView Earnings Details
5/9/2013Q1 2013($0.17)($0.24)ViewN/AView Earnings Details
3/18/2013Q4 2012($0.15)($0.17)ViewN/AView Earnings Details
11/13/2012Q312($0.01)($0.15)ViewN/AView Earnings Details
5/10/2012Q1 2012($0.13)ViewN/AView Earnings Details
3/15/2012Q4 2011($0.12)($0.12)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Synergy Pharmaceuticals (NASDAQ:SGYP) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Synergy Pharmaceuticals (NASDAQ SGYP) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 4.80%
Institutional Ownership Percentage: 44.32%
Insider Trading History for Synergy Pharmaceuticals (NASDAQ:SGYP)
Institutional Ownership by Quarter for Synergy Pharmaceuticals (NASDAQ:SGYP)

Synergy Pharmaceuticals (NASDAQ SGYP) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
11/10/2017Paulson & Co. Inc.Major ShareholderSell8,750,000$2.82$24,675,000.00View SEC Filing  
8/7/2017Paulson & Co. Inc.Major ShareholderSell26,287$3.77$99,101.99View SEC Filing  
5/26/2017Gary S JacobCEOBuy5,680$3.52$19,993.60402,679View SEC Filing  
5/26/2017John P BrancaccioDirectorBuy6,500$3.59$23,335.0030,444View SEC Filing  
11/4/2016Paulson & Co. Inc.Major ShareholderSell140,000$4.24$593,600.00View SEC Filing  
9/28/2016Paulson & Co. Inc.Major ShareholderSell54,300$5.69$308,967.00View SEC Filing  
9/19/2016John P BrancaccioDirectorSell2,518$5.76$14,503.6821,883View SEC Filing  
9/19/2016Paulson & Co. Inc.Major ShareholderSell3,473,713$5.61$19,487,529.93View SEC Filing  
9/14/2015Bernard DenoyerSVPSell10,000$7.50$75,000.00View SEC Filing  
9/11/2015Alan JoslynDirectorSell13,754$7.22$99,303.88View SEC Filing  
6/3/2014John P BrancaccioDirectorBuy3,500$4.12$14,420.00View SEC Filing  
5/27/2014Gary S JacobCEOBuy4,000$4.18$16,720.00View SEC Filing  
5/23/2014Bernard DenoyerSVPBuy2,500$3.89$9,725.00View SEC Filing  
5/23/2014Kunwar ShailubhaiInsiderBuy3,000$3.89$11,670.00View SEC Filing  
10/29/2013Gabriel CerroneDirectorBuy12,000$4.09$49,080.00View SEC Filing  
6/21/2013Bernard DenoyerSVPBuy7,500$4.78$35,850.00View SEC Filing  
6/14/2013Gabriel CerroneChairmanBuy8,000$4.42$35,360.00View SEC Filing  
4/24/2013Gabriel CerroneChairmanBuy5,500$4.66$25,630.00View SEC Filing  
2/5/2013Gabriel CerroneChairmanBuy5,000$6.15$30,750.00View SEC Filing  
2/4/2013Gabriel CerroneChairmanBuy13,090$6.04$79,063.60View SEC Filing  
1/30/2013Gabriel CerroneChairmanBuy26,000$5.98$155,480.00View SEC Filing  
11/14/2012Gabriel CerroneChairmanBuy87,820$3.61$317,030.20View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Synergy Pharmaceuticals (NASDAQ SGYP) News Headlines

Source:
DateHeadline
Synergy Pharmaceuticals Sees Exodus In Institutional Ownership As Management Ignores Dilution FearsSynergy Pharmaceuticals Sees Exodus In Institutional Ownership As Management Ignores Dilution Fears
seekingalpha.com - May 25 at 9:06 AM
FY2018 EPS Estimates for Synergy Pharmaceuticals Inc Lowered by Analyst (SGYP)FY2018 EPS Estimates for Synergy Pharmaceuticals Inc Lowered by Analyst (SGYP)
www.americanbankingnews.com - May 24 at 8:23 AM
Biotech CEO Presents: Merck’s $500M Pain, Our Potential GainBiotech CEO Presents: Merck’s $500M Pain, Our Potential Gain
finance.yahoo.com - May 22 at 8:56 AM
$11.60 Million in Sales Expected for Synergy Pharmaceuticals Inc (SGYP) This Quarter$11.60 Million in Sales Expected for Synergy Pharmaceuticals Inc (SGYP) This Quarter
www.americanbankingnews.com - May 22 at 2:12 AM
Zacks: Brokerages Anticipate Synergy Pharmaceuticals Inc (SGYP) Will Announce Earnings of -$0.16 Per ShareZacks: Brokerages Anticipate Synergy Pharmaceuticals Inc (SGYP) Will Announce Earnings of -$0.16 Per Share
www.americanbankingnews.com - May 20 at 9:28 PM
Synergy Pharmaceuticals Investors: Refocus Away From ManagementSynergy Pharmaceuticals Investors: Refocus Away From Management
seekingalpha.com - May 18 at 10:29 AM
Synergy Pharmaceuticals Evaluating All Options: Does That Mean A Formal Strategic Review?Synergy Pharmaceuticals 'Evaluating All Options': Does That Mean A Formal Strategic Review?
seekingalpha.com - May 17 at 9:21 AM
Q2 2018 EPS Estimates for Synergy Pharmaceuticals (SGYP) Lowered by OppenheimerQ2 2018 EPS Estimates for Synergy Pharmaceuticals (SGYP) Lowered by Oppenheimer
www.americanbankingnews.com - May 16 at 7:27 AM
Synergy Pharmaceuticals (SGYP) Given a $7.00 Price Target by BTIG Research AnalystsSynergy Pharmaceuticals (SGYP) Given a $7.00 Price Target by BTIG Research Analysts
www.americanbankingnews.com - May 15 at 1:07 PM
FY2021 EPS Estimates for Synergy Pharmaceuticals Lifted by Analyst (SGYP)FY2021 EPS Estimates for Synergy Pharmaceuticals Lifted by Analyst (SGYP)
www.americanbankingnews.com - May 15 at 8:35 AM
Edited Transcript of SGYP earnings conference call or presentation 10-May-18 8:30pm GMTEdited Transcript of SGYP earnings conference call or presentation 10-May-18 8:30pm GMT
finance.yahoo.com - May 14 at 4:43 PM
Synergy Pharmaceuticals (SGYP) PT Set at $7.00 by HC WainwrightSynergy Pharmaceuticals (SGYP) PT Set at $7.00 by HC Wainwright
www.americanbankingnews.com - May 14 at 12:42 PM
Synergy Pharmaceuticals (SGYP) Rating Reiterated by OppenheimerSynergy Pharmaceuticals (SGYP) Rating Reiterated by Oppenheimer
www.americanbankingnews.com - May 14 at 12:42 PM
Today’s Research Reports on Stocks to Watch: Regeneron Pharmaceuticals and Synergy PharmaceuticalsToday’s Research Reports on Stocks to Watch: Regeneron Pharmaceuticals and Synergy Pharmaceuticals
finance.yahoo.com - May 14 at 10:40 AM
Synergy Pharmaceuticals: The Short Covering Has BegunSynergy Pharmaceuticals: The Short Covering Has Begun
seekingalpha.com - May 13 at 9:37 AM
Synergy Pharmaceuticals (SGYP) Posts  Earnings Results, Beats Expectations By $0.01 EPSSynergy Pharmaceuticals (SGYP) Posts Earnings Results, Beats Expectations By $0.01 EPS
www.americanbankingnews.com - May 11 at 9:39 PM
Synergy Pharmaceuticals: Very Soft First Quarter Fuels The RevoltSynergy Pharmaceuticals: Very Soft First Quarter Fuels The Revolt
seekingalpha.com - May 11 at 4:52 PM
Head-To-Head Comparison: Synergy Pharmaceuticals (SGYP) & Tocagen (TOCA)Head-To-Head Comparison: Synergy Pharmaceuticals (SGYP) & Tocagen (TOCA)
www.americanbankingnews.com - May 11 at 3:06 PM
Benzingas Daily Biotech Pulse: FDA Panel Nod For Akcea, Synergys Revenue Miss, FDA Warns E-Liquid Makers AgainBenzinga's Daily Biotech Pulse: FDA Panel Nod For Akcea, Synergy's Revenue Miss, FDA Warns E-Liquid Makers Again
www.msn.com - May 11 at 10:13 AM
Synergy Pharma: 1Q Earnings SnapshotSynergy Pharma: 1Q Earnings Snapshot
www.cnbc.com - May 11 at 10:13 AM
Synergy Pharmaceuticals (SGYP) CEO Troy Hamilton on Q1 2018 Results - Earnings Call TranscriptSynergy Pharmaceuticals' (SGYP) CEO Troy Hamilton on Q1 2018 Results - Earnings Call Transcript
seekingalpha.com - May 11 at 10:13 AM
Synergy Pharmaceuticals Reports First Quarter 2018 Financial Results and Business UpdateSynergy Pharmaceuticals Reports First Quarter 2018 Financial Results and Business Update
finance.yahoo.com - May 10 at 4:43 PM
Synergy Pharmaceuticals: Activist Group Reaches 26.1 Million SharesSynergy Pharmaceuticals: Activist Group Reaches 26.1 Million Shares
seekingalpha.com - May 10 at 9:27 AM
Synergy Pharmaceuticals (SGYP) Lowered to Sell at Zacks Investment ResearchSynergy Pharmaceuticals (SGYP) Lowered to Sell at Zacks Investment Research
www.americanbankingnews.com - May 9 at 6:02 PM
Synergy Pharmaceuticals (SGYP) Lifted to "Sell" at ValuEngineSynergy Pharmaceuticals (SGYP) Lifted to "Sell" at ValuEngine
www.americanbankingnews.com - May 7 at 10:36 PM
HC Wainwright Analysts Give Synergy Pharmaceuticals (SGYP) a $7.00 Price TargetHC Wainwright Analysts Give Synergy Pharmaceuticals (SGYP) a $7.00 Price Target
www.americanbankingnews.com - May 7 at 2:56 PM
Synergy Pharmaceuticals (SGYP) Receives Consensus Recommendation of "Hold" from BrokeragesSynergy Pharmaceuticals (SGYP) Receives Consensus Recommendation of "Hold" from Brokerages
www.americanbankingnews.com - May 6 at 7:41 PM
Synergy Pharmaceuticals: Activist Group Reaches 20.6 Million SharesSynergy Pharmaceuticals: Activist Group Reaches 20.6 Million Shares
seekingalpha.com - May 6 at 4:48 PM
Zacks: Brokerages Expect Synergy Pharmaceuticals (SGYP) Will Announce Quarterly Sales of $10.70 MillionZacks: Brokerages Expect Synergy Pharmaceuticals (SGYP) Will Announce Quarterly Sales of $10.70 Million
www.americanbankingnews.com - May 5 at 3:43 AM
Zacks: Brokerages Anticipate Synergy Pharmaceuticals (SGYP) Will Announce Earnings of -$0.16 Per ShareZacks: Brokerages Anticipate Synergy Pharmaceuticals (SGYP) Will Announce Earnings of -$0.16 Per Share
www.americanbankingnews.com - May 3 at 5:56 PM
Synergy Pharmaceuticals (SGYP) to Release Quarterly Earnings on ThursdaySynergy Pharmaceuticals (SGYP) to Release Quarterly Earnings on Thursday
www.americanbankingnews.com - May 3 at 3:32 AM
Synergy Pharmaceuticals Is Facing A Shareholder Revolt - GoodSynergy Pharmaceuticals Is Facing A Shareholder Revolt - Good
seekingalpha.com - May 1 at 9:07 AM
Synergy Pharmaceuticals: Q1 Earnings PreviewSynergy Pharmaceuticals: Q1 Earnings Preview
seekingalpha.com - April 30 at 10:18 AM
Synergy Pharmaceuticals Investors Ask Ackman And Icahn To InterveneSynergy Pharmaceuticals Investors Ask Ackman And Icahn To Intervene
seekingalpha.com - April 30 at 10:18 AM
Synergy Pharmaceuticals to Report First Quarter 2018 Financial Results and Host Conference Call and WebcastSynergy Pharmaceuticals to Report First Quarter 2018 Financial Results and Host Conference Call and Webcast
finance.yahoo.com - April 25 at 9:41 AM
Synergy Pharmaceuticals (SGYP) Stock Rating Reaffirmed by BTIG ResearchSynergy Pharmaceuticals (SGYP) Stock Rating Reaffirmed by BTIG Research
www.americanbankingnews.com - April 20 at 4:17 PM
Options Traders Expect Huge Moves in Synergy Pharmaceuticals (SGYP) StockOptions Traders Expect Huge Moves in Synergy Pharmaceuticals (SGYP) Stock
finance.yahoo.com - April 18 at 9:35 AM
Synergy Pharmaceuticals (SGYP) Expected to Earn Q1 2018 Earnings of ($0.15) Per ShareSynergy Pharmaceuticals (SGYP) Expected to Earn Q1 2018 Earnings of ($0.15) Per Share
www.americanbankingnews.com - April 18 at 7:42 AM
-$0.16 EPS Expected for Synergy Pharmaceuticals (SGYP) This Quarter-$0.16 EPS Expected for Synergy Pharmaceuticals (SGYP) This Quarter
www.americanbankingnews.com - April 16 at 9:21 AM
Synergy Pharmaceuticals (SGYP) Given a $13.00 Price Target by Canaccord Genuity AnalystsSynergy Pharmaceuticals (SGYP) Given a $13.00 Price Target by Canaccord Genuity Analysts
www.americanbankingnews.com - April 15 at 8:37 AM
Synergy Pharmaceuticals (SGYP) Receives Average Recommendation of "Hold" from BrokeragesSynergy Pharmaceuticals (SGYP) Receives Average Recommendation of "Hold" from Brokerages
www.americanbankingnews.com - April 11 at 6:19 PM
Synergy Pharmaceuticals (SGYP) Earns Buy Rating from Cantor FitzgeraldSynergy Pharmaceuticals (SGYP) Earns Buy Rating from Cantor Fitzgerald
www.americanbankingnews.com - April 11 at 6:13 PM
Synergy Pharmaceuticals (SGYP) Given a $9.00 Price Target by Oppenheimer AnalystsSynergy Pharmaceuticals (SGYP) Given a $9.00 Price Target by Oppenheimer Analysts
www.americanbankingnews.com - April 11 at 1:27 PM
HC Wainwright Analysts Give Synergy Pharmaceuticals (SGYP) a $15.00 Price TargetHC Wainwright Analysts Give Synergy Pharmaceuticals (SGYP) a $15.00 Price Target
www.americanbankingnews.com - April 11 at 12:11 AM
SGYP DEADLINE TODAY: The Law Offices of Vincent Wong Reminds Investors of Class Actions Involving Synergy Pharmaceuticals Inc. and a Lead Plaintiff Deadline of April 10, 2018SGYP DEADLINE TODAY: The Law Offices of Vincent Wong Reminds Investors of Class Actions Involving Synergy Pharmaceuticals Inc. and a Lead Plaintiff Deadline of April 10, 2018
finance.yahoo.com - April 10 at 4:40 PM
FINAL DEADLINE ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Synergy Pharmaceuticals Inc. (SGYP) & Lead Plaintiff Deadline: April 10, 2018FINAL DEADLINE ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Synergy Pharmaceuticals Inc. (SGYP) & Lead Plaintiff Deadline: April 10, 2018
finance.yahoo.com - April 10 at 4:40 PM
Glancy Prongay & Murray LLP Reminds Investors of the April 10, 2018 Deadline in the Class Action Lawsuit Against Synergy Pharmaceuticals Inc. (SGYP)Glancy Prongay & Murray LLP Reminds Investors of the April 10, 2018 Deadline in the Class Action Lawsuit Against Synergy Pharmaceuticals Inc. (SGYP)
finance.yahoo.com - April 10 at 4:40 PM
DEADLINE TODAY: The Schall Law Firm Announces the Filing of a Securities Class Action Lawsuit Against Synergy Pharmaceuticals Inc. and Reminds Investors With Losses In Excess of $50,000 to Contact The FirmDEADLINE TODAY: The Schall Law Firm Announces the Filing of a Securities Class Action Lawsuit Against Synergy Pharmaceuticals Inc. and Reminds Investors With Losses In Excess of $50,000 to Contact The Firm
finance.yahoo.com - April 10 at 4:40 PM
Glancy Prongay & Murray LLP Announces the Filing of a Securities Class Action on Behalf of Synergy Pharmaceuticals ...Glancy Prongay & Murray LLP Announces the Filing of a Securities Class Action on Behalf of Synergy Pharmaceuticals ...
www.businesswire.com - April 10 at 9:29 AM
EQUITY NOTICE: Rosen Law Firm Reminds Synergy Pharmaceuticals Inc. Investors of Important April 10, 2018 ...EQUITY NOTICE: Rosen Law Firm Reminds Synergy Pharmaceuticals Inc. Investors of Important April 10, 2018 ...
www.businesswire.com - April 10 at 9:29 AM

SEC Filings

Synergy Pharmaceuticals (NASDAQ:SGYP) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Synergy Pharmaceuticals (NASDAQ:SGYP) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Synergy Pharmaceuticals (NASDAQ SGYP) Stock Chart for Sunday, May, 27, 2018

Loading chart…

This page was last updated on 5/27/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.